Evidence map›Paper›PMID 35145788›Full record

ArticleCureus2022

Warfarin-Induced Skin Necrosis Despite Enoxaparin Bridging Therapy.

Mohamed Wali, Muhammad T Latif, Mary Lockwood, Ayman Saeyeldin, Carolina Borz-Baba

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Mohamed WaliInternal Medicine, Frank H. Netter M.D. School of Medicine at Quinnipiac University, North Haven, USA.
Muhammad T LatifInternal Medicine, Saint Mary's Hospital, Waterbury, USA.
Mary LockwoodInternal Medicine, NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn, USA.
Ayman SaeyeldinInternal Medicine, Saint Mary's Hospital, Waterbury, USA.
Carolina Borz-BabaInternal Medicine, Saint Mary's Hospital, Waterbury, USA.
NewYork–Presbyterian Brooklyn Methodist Hospital · USQuinnipiac University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Skin necrosis is a rare albeit severe complication of warfarin use for anticoagulation, resulting in significant morbidity and mortality. Here, we present the case of a 58-year-old woman who developed erythema and pain in her left leg two weeks after initiation of warfarin therapy with concomitant early administration of heparin for a deep vein thrombosis and pulmonary embolism. Subsequently, the erythema progressed to skin necrosis, and a diagnosis of warfarin-induced skin necrosis (WISN) was suspected. Warfarin was discontinued, and unfractionated heparin was commenced. The simultaneous presence of eosinophilia pointed toward an associated drug-related hypersensitivity reaction. Dexamethasone was added to the medication regimen. The patient was discharged on a factor Xa inhibitor and prednisone. Recognizing WISN is crucial in patients receiving anticoagulation. The diagnosis can be particularly challenging in cases when bridging anticoagulation has been previously completed. Early diagnosis and drug discontinuation are critical to ensuring a favorable prognosis. Steroids may also play a role in the treatment of this condition if an associated drug hypersensitivity is identified.

Indexed as

bridging anticoagulationdrug-induced hypersensitivitydrug rashenoxaparinwarfarin-induced skin necrosiswarfarin therapy

Identifiers

PMID35145788
PMCPMC8808085
OpenAlexW4206684587

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.